Mudd’s disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes

Citation: Chien, Y., J. E. Abdenur, F. Baronio, A. A. Bannick, F. Corrales, M. Couce, M. G. Donner, et al. 2015. “Mudd’s disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes.” Orphanet Journal of Rare Diseases 10 (1): 99. doi:10.1186/s13023-015-0321-y. http://dx.doi.org/10.1186/s13023-015-0321-y.

Published Version: doi:10.1186/s13023-015-0321-y

Citable link: http://nrs.harvard.edu/urn-3:HUL.InstRepos:21462299

Terms of Use: This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Mudd’s disease (MAT I/III deficiency): a survey of data for MAT1A homozygotes and compound heterozygotes

Yin-Hsiu Chien1, Jose E. Abdenur2, Federico Baronio3, Allison Anne Bannick4, Fernando Corrales5, Maria Couce6, Markus G. Donner7, Can Ficiçioglu8, Cynthia Freehaut9, Deborah Frithiod10, Garrett Gotway11, Koichi Hirabayashi12, Floris Hofstede13, George Hoganson14, Wuh-Liang Hwu15, Philip James16, Sook Kim17, Stanley H. Korman17, Robin Lachmann18, Harvey Levy15, Martin Lindner19,20, Lilia Lykopoulou21, Ertan Mayatepek22, Ania Muntau23, Yoshiyuki Okano24, Kimiyoshi Raymond25, Estela Rubio-Gozalbo26, Sabine Scholl-Bürgi27, Andreas Schulze28, Rani Singh29, Sally Stabler30, Mary Stuy31, Janet Thomas9, Conrad Wagner32, William G. Wilson33, Saskia Wortmann34, Shigenori Yamamoto35, Maryland Pao36 and Henk J. Blom37*

Abstract

Background: This paper summarizes the results of a group effort to bring together the worldwide available data on patients who are either homozygotes or compound heterozygotes for mutations in MAT1A. MAT1A encodes the subunit that forms two methionine adenosyltransferase isoenzymes, tetrameric MAT I and dimeric MAT III, that catalyze the conversion of methionine and ATP to S-adenosylmethionine (AdoMet). Subnormal MAT I/III activity leads to hypermethioninemia. Individuals with hypermethioninemia due to one of the MAT1A mutations that in heterozygotes cause relatively mild and clinically benign hypermethioninemia are currently often being flagged in screening programs measuring methionine elevation to identify newborns with defective cystathionine β-synthase activity. Homozygotes or compound heterozygotes for MAT1A mutations are less frequent. Some but not all, such individuals have manifested demyelination or other CNS abnormalities.

Purpose of the study: The goals of the present effort have been to determine the frequency of such abnormalities, to find how best to predict whether they will occur, and to evaluate the outcomes of the variety of treatment regimens that have been used. Data have been gathered for 64 patients, of whom 32 have some evidence of CNS abnormalities (based mainly on MRI findings), and 32 do not have such evidence.

Results and Discussion: The results show that mean plasma methionine concentrations provide the best indication of the group into which a given patient will fall: those with means of 800 μM usually have evidence of CNS abnormalities, whereas those with lower means usually do not. Data are reported for individual patients for MAT1A genotypes, plasma methionine, total homocysteine (tHcy), and AdoMet concentrations, liver function studies, results of 15 pregnancies, and the outcomes of dietary methionine restriction and/or AdoMet supplementation. Possible pathophysiological mechanisms that might contribute to CNS damage are discussed, and tentative suggestions are put forth as to optimal management.

* Correspondence: henk.blom@uniklinik-freiburg.de
37 Laboratory for Clinical Biochemistry and Metabolism, Center for Pediatrics and Adolescent Medicine University Hospital Freiburg, 79106 Freiburg, Germany
Full list of author information is available at the end of the article

© 2015 Chien et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

More than sixty years ago Giulio Cantoni described an enzyme that utilized methionine and ATP to form a then novel product needed for transmethylation reactions [1], which he soon identified as S-adenosylmethionine (AdoMet) [2]. Since then, AdoMet has turned out to be among the most versatile compounds in all of biology. In humans AdoMet is used by as many as 200 or more methyltransferases [3]; after decarboxylation, as a source of aminopropyl groups in polyamine biosynthesis [4]; possibly as a source of other moieties [5]; and as a regulator of sulfur amino acid metabolism [6] and liver function [7]. Evidence has been presented that humans have a few enzymes that, as members of the group of more than 2800 proteins that comprise the biologically widespread radical SAM superfamily, use a 5′-deoxyadenosyl radical derived from AdoMet [8]. The structure of methionine adenosyltransferase (MAT)(E.C. 2.5.1.6), the enzyme that synthesizes AdoMet has been highly conserved during evolution: in a study of 292 MAT genes occurring in bacteria and eukaryota there was perfect conservation of active site residues, approximately 30% of the encoded amino acids were identical in all species [9]. Humans possess two genes encoding isoforms of MAT: MATIA encodes a catalytic subunit that forms the tetrameric and dimeric holoenzymes, MAT I and MAT III. MAT2A encodes the catalytic subunit of MAT II [10]. Sánchez-Pérez et al. found that each vertebrate included in their study had two MAT genes that encoded amino acid sequences with about 85% identity, suggesting a gene duplication that occurred after the human lineage diverged from the sea squirts (Urochordata), but before divergence from the jawed vertebrates (Teleostomi) [9], perhaps 400–500 million years ago. MAT II is the major isozyme in non-hepatic tissues and in fetal liver, whereas MAT I and III are the major forms present in post-natal liver [10]. However, MATIA expression has been reported in pancreas [11] and, more recently, in small amounts in most tissues, including brain [12]. After the introduction of screening newborns for methionine elevations to detect homocystinuria due to cystathionine β-synthase deficiency, infants were discovered in the United States [13], France [14], and Japan [15] with elevated blood methionine but without abnormal levels of homocystine, and MAT activities were shown to be low in extracts of their livers [13, 15–18], as well as in that of an adult patient found to be hypermethioninemic when investigated because of malodorous breath due to dimethylsulfide [19, 20]. The kinetic properties of the residual hepatic MAT activities of these patients [16, 19] as well as the finding that MAT activities in a variety of their non-hepatic tissues were normal indited that the defective activity was that encoded by MATIA [16, 17, 21]. Establishment of the amino acid sequence encoded by MATIA [22–24] then opened the way to finding MATIA mutations in most of the patients in question [25–27]. As screening of newborns for methionine elevations has expanded, MATIA mutations are turning out to be the most common genetic cause of newborn hypermethioninemia [28–31]. Most such cases are heterozygous for R264H, a mutation in which the activity of wild-type subunits is suppressed by combination with mutant subunits [32, 33]. Several other such dominant mutations have now been identified [31, 34, 35]. Clinically, heterozygotes for such mutations have been unaffected. However, in addition, a number of patients with homozygous or compound heterozygous MATIA mutations have been found through newborn screening [30, 31, 36–44], and although some of these patients have been clinically unaffected, some of them have had brain demyelination or other MRI abnormalities. Treatments used have included dietary methionine restriction or supplementation with AdoMet, but optimal management has not yet been clearly established. With the aim of providing information on the criteria for prognosis and optimal treatment of such patients we have recently made an effort to collect as much information as possible on the clinical status and outcomes and the metabolic details of patients for whom sequencing has shown either homozygous or compound heterozygous MATIA mutations, or those with hypermethioninemia and deficient MAT activities. The findings are presented and discussed in this paper.

Methods

A literature search was carried out to identify patients who had been found to be homozygotes or compound heterozygotes for MATIA mutations or who, although not genotyped, had been shown to have deficient activities of hepatic MAT. Information on such patients was taken from relevant publications and analyzed together, whenever possible, with updated information submitted by coauthors based on their experiences in management of, or diagnostic studies of, the patients in question. In addition, physicians taking care of MAT I/III patients came known to the authors via support in the diagnostic process or counseling on potential treatment of these patients. Informed consent was obtained from the patients or their parents and local ethical rules were followed. Ethical approval was obtained from the Office of Human Subjects Research (OHSR) at the NIH, Bethesda, USA.

Patients were considered to have “CNS abnormality” if their brain MRI showed abnormalities or if presence of any neurological symptom was reported or both.

In Tables 1 and 2 the references are given of those patients that have been published before.
Table 1 Patients without evidence of CNS abnormalities

| Patient | Sex | Age at last report years | MAT1A allele 1/allele 2 | MAT activity % of WT | Cause ascertainment | Age < 5 m Met age range | Age ≥ 5 m Met mean ± SD | MRI (age) | Citation |
|---------|-----|--------------------------|-------------------------|---------------------|---------------------|------------------------|------------------------|------------|----------|
| G1      | F   | 40.4                     | c.966T>G (p.Ile322Met)  | 7.8*                | NBS                 | 1270                   | 373 ± 133              | Normal (22) | [17, 25, 46, 58] |
| G2      | M   | 38                       | c.914T>C (p.Leu305Pro)  | 10.2*               | NBS                 | 364–583                | 394 ± 118              | —           | [17, 25] |
| G3      | F   | 2                        | c.164C>A (p.Arg55Asp)   | 10.91*              | NBS                 | 389–1020               | 315                    | —           | [17, 25] |
| G4      | F   | 31.4                     | c.1068G>A (p.Arg356Gln) | 17.5*               | NBS                 | 42–408                 | 146 ± 38               | —           | [17, 26] |
| G5      | M   | 60.1                     | c.539insTG (p.Thr185X)  | 28*                 | Breath odor         | —                      | 805 ± 106              | Normal (31) | [19, 20, 78] |
| G6      | F   | 21.5                     | c.539insTG (p.Thr185X)  | NA                  | NBS                 | 1870                   | 777 ± 169              | Normal (6)   | [26, 58] |
| 10a     | M   | 25                       | c.595C>T (p.Arg199Cys)  | 11/11               | NBS                 | 496–670                | 520 ± 124              | —           | [26, 58] |
| 11a     | F   | 28.5                     | c.595C>T (p.Arg199Cys)  | 11/11               | NBS                 | 591–654                | 475 ± 118              | —           | [26, 58] |
| 14      | F   | 6.4                      | c.966T>G (p.Ile322Met)  | 11/11               | NBS                 | 440–467                | 225 ± 57               | —           | [27, 58] |
| 15b     | F   | 2.2                      | c.1132G>A (p.Gly378Ser) | 0.2/75              | NBS                 | 383–1089               | 519                    | —           | [80]     |
| 16b     | F   | 4.7                      | c.1132G>A (p.Gly378Ser) | 0.2/75              | Family              | —                      | 782 ± 400              | —           | [80]     |
| 17      | F   | 21.4                     | c.791C>T (p.Arg264Cys)  | 0.3/31              | NBS                 | 648                    | 322                    | —           | [42]     |
| 18      | M   | 21.2                     | c.1070C>T (p.Pro357Leu) | 31/31               | NBS                 | 505                    | 325 ± 244              | —           | [42]     |
| 19      | F   | 16.5                     | c.1067G>C (p.Arg356Pro) | 11/31               | NBS                 | 622                    | 175                    | —           | [34, 42] |
| 21      | F   | 7.1                      | c.836G>T (p.Gly279Val)  | NA/2                | NBS                 | 596                    | 436 ± 1                | —           | [34]     |
| 23      | F   | 3.9                      | c.539insTG (p.Thr185X)  | NA                  | NBS                 | 216–1457               | 665 ± 160              | —           | [38]     |
| 24c     | M   | 1.2                      | c.689T>G (p.Val230Gly)  | NA                  | NBS                 | 518–525                | 769 ± 112              | —           |         |
| 25c     | F   | 4.9                      | c.689T>G (p.Val230Gly)  | NA                  | NBS                 | 838 ± 18               | —                      | —           |         |
| 26      | F   | 2.9                      | c.527T>A (p.Leu176Gln)  | NA                  | NBS                 | 57–200                 | 76 ± 24                | —           |         |
| 28      | F   | 20                       | c.65C>T (p.Ser22Leu)    | 46/46               | NBS                 | —                      | 975 ± 177              | normal (20) | [34, 37, 44] |
| 33      | U   | 2                        | c.856G>A (p.Asp286Asn)  | NA                  | NBS                 | 106–1570               | del at least exon 6-8 | —           |         |
| 40      | F   | 0.4                      | c.1141G>A (p.Gly381Arg)| 25/25               | NBS                 | 1207–2121              | 1673                   | —           | [34]     |
### Results

#### Summary tables
Currently data are available for 64 patients. Because a substantial portion of these patients have evidence of CNS abnormalities, we divided them between those without (Table 1) \((n = 32)\) and with evidence of CNS abnormalities (Table 2) \((n = 32)\). These Tables show many more important features of the patients, including their MAT1A genotypes, their age at last report, cause of ascertainment, plasma methionine concentrations and whether MRI's, if performed, were normal or abnormal. Tables 3 and 4 present the brief clinical histories of the patients with possible CNS abnormalities, the interventions used (if any), and the MRI findings at specified ages.

#### Possible criteria to distinguish between those with and without CNS problem (Tables 1 and 2)

**MAT1A genotypes**
MAT1A genotypes are not clearly predictive. Patients with homozygous truncating mutations with presumably no residual MAT I/III activity are found among those without CNS problems (patients 2 and 3), and most of the patients with CNS problems have only missense mutations which, when expressed in *E. coli*, had some residual MAT activities.

**Plasma methionine concentrations**
For untreated patients for whom more than one value for plasma methionine during the first few months of life were available, values often varied relatively widely (Fig. 1). After that time methionine concentrations tended to be less variable for a given patient. As shown in Fig. 2, on normal diets mean methionine values for patients with evidence of CNS abnormalities were usually higher than were those for patients without evidence of such abnormalities. Those with mean values above 800 μM almost always have CNS abnormalities, whereas those with means less than 800 μM usually do not. In the total group (all ages) three patients with CNS abnormalities were below 800 μM and six patients without

### Table 1 Patients without evidence of CNS abnormalities (Continued)

| Patient ID | Sex | Age | Genotype | Methionine Concentration | MRI | Other Information |
|------------|-----|-----|----------|--------------------------|-----|-------------------|
| 44         | M   | 0.2 | c.1141G>A (p.Gly381Arg) | – | 97 | – |
| 48         | M   | 5.4 | c.529C>T (p.Arg177Trp) | – | 134 | 134–1567 Normal (yearly, final at 5) DQ 88 |
| 49         | F   | 0.3 | c.110T>C (p.Ile37Thr) | 403–408 | NBS 407 | – |
| 52         | M   | 0.54 | c.529C>T (p.Arg177Trp) | – | NBS 407 | 949–1074 normal (0.5) |
| 53         | F   | 2.3 | c.823G>C (p.Gly275Arg) | – | NBS | 121–484 495 ± 275 |
| 54         | F   | 2.0 | c.823G>C (p.Gly275Arg) | – | NBS | 185–410 |
| 57         | U   | 3.5 | c.169+1G>A | – | NBS | 860–1130 918 ± 84 |
| 58d        | M   | 12.3 | not sequenced | 22.7* | NBS | 268–1005 369 ± 237 |
| 59d        | M   | 13.7 | not sequenced | 23.1* | Family | – 350 ± 50 |
| 64         | M   | 4.5 m | c.596G>A (p.Arg199His) | – | NBS | 118–208 |

*Patients are assigned the same identifiers as were used when they were first described in the following papers: Patients G1, G2, G3, G4 [17]; Patients 3, 10, 11 [58]; Patients 17, 18, 19; numbers 1, 2 and 5 [42]; Patient 28: patient 1 [44]; Patients 53, 54: patients 14 and 18 [30]*

*Activity based on assay of hepatic extract; others based on activity of mutant recombinant forms expressed in *E. coli* [34]*

*Sibs are designated by the same superscript*  
†Cont. indicates that methionine restriction or AdoMet supplementation was continuing at last report  
NBS: Newborn screening  
NA: not available  
Met: methionine concentration in μmol/L.
CNS abnormalities were above 800 μM. The respective means (± SD) for these two groups were 1073 μM ± 233 and 485 μM ± 276.

**Plasma AdoMet concentrations**

Data for the available concentrations of plasma AdoMet at age ≥ 5 months are shown in Fig. 3. Although, as already shown in Fig. 2, most patients with evidence of CNS abnormalities have higher plasma methionines, there is no trend for a difference in the AdoMet concentrations between those with and without such evidence, and the mean values (± SD) were, respectively 84 nM ± 19 and 72 nM ± 13.

**Plasma total homocysteine (tHcy) values**

Figure 4 shows values of plasma methionine and tHcy for the individual samples in which both of these were assayed. To provide more indication of the range of values encountered at young ages, points are plotted for samples drawn either before (circles) or after (triangles) age 5 months. As plasma methionine rises, tHcy tends to rise also, so that patients with evidence of CNS abnormalities tend to have higher levels of tHcy. However at the higher methionine concentrations there is no apparent difference in the tHcy values between those with and without CNS abnormalities, indicating the response to methionine elevation is about the same in the two groups.

**Plasma cystathionine values**

Among the few patients for whom sensitive serial assays of cystathionine were performed at early ages cystathionines were mildly elevated at 16 days, 21 days, 38 days and 1.5 months with values, respectively of 776, 1196, 1280, and 1001 nM (adult reference range 44–342 nM). Values had fallen to 566 and 670 nM by 11 months and thereafter were, at most, only slightly above the reference range (data not shown in Tables).

**Liver function studies**

The results of liver function studies are available for 16/32 patients without and 14/32 of those with evidence of CNS abnormalities. Included are assays (in some patient multiple times) of ALT and AST, total bilirubin, alkaline phosphatase, albumin, total plasma protein, and gamma glutamyltranspeptidase. No instances of hepatic malfunction have been detected by these studies (data not shown in Tables).

**Pregnancy outcomes**

Information is available on 15 pregnancies among six of the present patients:

*Patient G1* had four pregnancies. Because the patient’s plasma choline was below the reference range, and because brain damage occurs in fetuses of experimental animal mothers fed low choline diets [45], she was advised after gestation week 17 in three of these pregnancies to ingest two eggs daily to provide about 630 mg choline/day. Three normal children were born who have continued to develop normally mentally and physically. In the fourth pregnancy there were no overt complications but sonography at ten weeks disclosed fetal arrest and the pregnancy was terminated two weeks later [46].

*Patient G4* took 600 mg choline/day during most of her initial pregnancy and produced a normal baby. During a second pregnancy she took 2 eggs/day from 18 weeks gestation, and then changed to choline capsules, 600 mg/d during the remainder of the pregnancy. A normal child was born who continued to be normal at last investigation at age 6 months.

*Patient 3* had been temporarily lost to follow-up, but was relocated and found to have produced a normal baby without any specific treatment due to her MAT I/III deficiency.

*Patient 5* had also been lost to follow-up after childhood, but was found again when she produced a baby that was flagged during NBS for elevated methionine that turned out to be transient [47].

*Patient 4* produced a normal baby after a pregnancy during which she continued her usual dose of AdoMet, 200 mg bid.

*Patient 56* was ascertained at age 38 with elevated methionine and tHcy because she had given birth to two children with transient hypermethioninemia (NBS methionines of 552 and 554 μM, falling to 94 μM on day 5 or 42 μM on day 4 of life). Her history revealed that she had had six pregnancies with one lost at 4 weeks, a stillborn at 16 weeks, two blighted ovums and another 2 with transient hypermethioninemia.

**Treatment outcomes**

**Vitamin B6**

Because of the mild elevations of tHcy often encountered in *MAT1A* deficient patients, 6 of the 32 without and 7 of the 32 with evidence of CNS abnormalities (data not shown in Tables) have been given brief trials of high doses of vitamin B6. In almost all cases there were no significant effects. One patient (#36) did experience a marked decrease in plasma methionine during an initial period of B6 treatment, but that response did not occur during a second trial nor in her identical twin sister (#37). In addition, even some adverse events were reported in patients using high doses of B6 [48]. One MAT I/III deficient infant (#7) became apneic and required respiratory support shortly after starting a dose of pyridoxine of 500 mg/day [49], and Tada et al. reported that pyridoxine treatment may have
| Patient | Sex | Age at last report years | MAT1A allele 1/allele 2 | MAT activity % of WT | Cause ascertainment | Age < 5 m Met range | Age ≥ 5 m Met mean ± SD | MRI (age done) | Other | Citation |
|---------|-----|--------------------------|------------------------|---------------------|---------------------|---------------------|----------------------|----------------|-------|----------|
| 1       | M   | 24.2                     | c.113G>A (p.Ser38Asp)  | 8%                  | NBS                 | 670–1237            | 1030                 | Abnormal (20.7) |       | [14, 16, 27, 58] |
|         |     |                          | c.255delCA (p.Tyr92X)  |                     |                     |                     |                      |                 |       |          |
| 4       | F   | 32                       | c.827T>G (p.Lys351X)   |                     | NA                  | —                   | 600–1400             | Abnormal (11)   |       | [26, 64] |
|         |     |                          | c.827T>G (p.Lys351X)   |                     |                     |                      |                      |                 |       |          |
| 5       | F   | 26.1                     | c.791C>T (p.Arg264Cys) | 0.3/23              | NBS                 | 201                 | 909 ± 272            | Normal (13)    | IQ 84 (14) Learning disability (14) |
|         |     |                          | c.1006G>A (p.Gly336Arg)|                     | 201                 |                      |                      |                 |       |          |
| 7       | M   | 17.8                     | c.292G>A (splicing)    | NA                  | NBS                 | 1226                | 1428 ± 320           | Normal (0.75)  |       | [27, 58] |
|         |     |                          | c.292G>A (splicing)    |                     |                     |                      |                      |                 |       |          |
| 8       | F   | 13.6                     | c.1043delTG (p.His350X)| NA                  | Dystonia            | —                   | 1157 ± 445           | Abnormal (9)   |       | [26, 58] |
| 9       | M   | 8.7                      | c.595C>T (p.Arg199Cys) | 11/NA               | NBS                 | 966–1467            | 879 ± 140            | Normal (6)     | IQ 65 (6) |
|         |     |                          | c.595C>T (p.Arg199Cys) |                     |                     |                      |                      |                 |       |          |
| 13      | F   | 6.2                      | c.595C>T (p.Arg199Cys) | 11/11               | NBS                 | 635–738             | 485 ± 49             | Abnormal (8)   | Slow at school (16) |
|         |     |                          | c.595C>T (p.Arg199Cys) |                     |                      |                      |                      |                 |       |          |
| 20      | F   | 10.8                     | c.200G>A (p.Gly60Ser)  | 109/NA              | NBS                 | —                   | 1400                | Abnormal (10)  |       | [42]     |
|         |     |                          | c.1188G>T (p.X969Y5X464)| 1560               |                     |                      |                      |                 |       |          |
| 22      | F   | 7.5                      | c.874C>T (p.Arg292Cys) | 14/NA               | NBS                 | 1005–1676           | Abnormal (2.9)      | Normal (6.4)  | IQ 60 (5.4) |
|         |     |                          | c.1067G>T (p.Arg356Leu)| 395                |                     |                      |                      |                 |       |          |
| 29      | M   | 14.2                     | c.125T>C (p.Leu42Pro)  | 10/10               | NBS                 | 121–1541            | 1437 ± 498          | Abnormal (13)  | IQ 73 (13) |
|         |     |                          | c.125T>C (p.Leu42Pro)  |                     |                      |                      |                      |                 |       |          |
| 30*     | M   | 7.0                      | c.274T>C (p.Tyr92His)  | 104/11              | NBS                 | 740                 | 830 ± 368           | IQ 121 (3)     | Abnormal (3.8) Better (5.5) Normal (7) |
|         |     |                          | c.1067G>C (p.Arg356Pro)|                     | 395                |                      |                      |                 |       |          |
| 31*     | M   | 3                        | c.274T>C (p.Tyr92His)  | 104/11              | NBS                 | 820–2250            | 900–1140            | Abnormal (0.8) |       | [34, 41] |
|         |     |                          | c.1067G>C (p.Arg356Pro)|                     | 395                |                      |                      |                 |       |          |
| 32      | M   | 9.4                      | c.433G>A (p.Glu145Lys) | NA/14               | NBS                 | 1740–1870           | 740–1150            | Abnormal (5)   |       | [34, 43] |
|         |     |                          | c.874C>T (p.Arg292Cys) |                     | 395                |                      |                      |                 |       |          |
| 34      | M   | 0.63                     | c.1068G>A (p.Arg356Trp)| 4/4                 | NA                  | 1846–3500           | —                   | Severe retarded |       | [34]     |
|         |     |                          | c.1068G>A (p.Arg356Trp)|                     | 395                |                      |                      |                 |       |          |
| 35      | F   | 2.8                      | c.292G>A (splicing)    | NA/11               | NBS                 | 1544–1685           | 1159                | Abnormal (1.2) | Better (1.8) |
|         |     |                          | c.595C>T (p.Arg199Cys) |                     |                      |                      |                      |                 |       |          |
| 36†     | F   | 1.3                      | c.595C>T (p.Thr185X)   | NA/20               | NBSt                | 1400                | 1549                | Normal (2.3)  | Delayed development (2.3) |
|         |     |                          | c.890C>A (p.Ala297Asp)| 1400               |                     |                      |                      |                 |       |          |
| 37†     | F   | 1.3                      | c.595C>T (p.Thr185X)   | NA/20               | NBSt                | 1400–1421           | 1614                | Delayed development (2.3) |
|         |     |                          | c.890C>A (p.Ala297Asp)| 1400               |                     |                      |                      |                 |       |          |
| 38†     | F   | 13                       | c.896G>A (p.Arg299His)| 13/13               | Neuro-logical       | –                   | 1016 ± 549          | Abnormal (12.8)|       | [34]     |
|         |     |                          | c.896G>A (p.Arg299His)|                     | 395                |                      |                      |                 |       |          |
worsened the MRI and neurological abnormalities in their patient (#30) [36]. Taken together, high doses of vitamin B6 should not be used in patients with MAT I/III deficiency.

### Dietary methionine restriction

Methionine restriction has been used for 8/32 patients without CNS abnormalities and 16/32 patients with CNS abnormalities, starting at various ages and continued for a
### Table 3 Outcomes for treated patients

| Patient # | Diet | Start years | End years | Met μM Mean ± SD (N) | MRI | Clinical |
|-----------|------|-------------|-----------|----------------------|-----|----------|
| Patients without evidence of CNS problems who had periods of dietary methionine restriction |
| 3         | Normal | 4.5 m       | 2262 ± 350 (3) |             |     | Normal (21.5 y) |
|           | Restricted | 3.4 y | 462 ± 70 (5) | Normal (6 y) |     |          |
|           | Normal | 21.5 y | 777 ± 169 (8) |             | Normal (21.5 y) |
| 17        | Normal | 0.8 m       | 648 (1) |             |     |          |
|           | Restricted | 21.4 y | 282 ± 42 (3) | n.d. |     |          |
|           | Normal | 22.4 y | 314 (1) |             | Normal (21.4 y) |
| 18        | Normal | 1.0 m       | 305 (1) |             |     |          |
|           | Restricted | 1.4 y | 135 ± 40 (3) | n.d. |     |          |
|           | Normal | 21.5 y | 777 ± 169 (8) |             | Normal (21.5 y) |
| 19        | Normal | 0.8 m       | 648 (1) |             |     |          |
|           | Restricted | 21.4 y | 282 ± 42 (3) | n.d. |     |          |
|           | Normal | 22.4 y | 314 (1) |             | Normal (21.4 y) |
| 21        | Normal | 0.4 m       | 596 (1) |             |     |          |
|           | Restricted | 5.8 y | 282 ± 95 (6) | n.d. |     |          |
|           | Normal | 1.2 y | 436 ± 1 (2) | Normal (7.1 y) |
| 48        | Normal | 1.0 m       | 643 ± 646 (3) |             |     |          |
|           | Restricted | 1.5 y | 545 ± 118 (50) | n.d. |     |          |
|           | Normal | 26.1 y | 909 ± 272 (3) |             | Normal (21.5 y) |
| 53        | Normal | 0.4 m       | 536 (1) |             |     |          |
|           | Restricted | 1.0 m | 134–268 (2) | n.d. |     |          |
|           | Normal | 6.5 m | 67–268 (2) | n.d. |     |          |
| 58        | Normal | 0.6 m       | 263 ± 83 (7) |             | No problems (6 y) |
|           | Restricted | 6.6 m | 783 ± 337 (3) |             | Normal (6 y) |

| Patients with evidence of CNS problems who had periods of dietary methionine restriction |
|-----------|------|-------------|-----------|----------------------|-----|----------|
| 1         | Normal | 2.0 m       | 954 ± 401 (2) |             |     | Normal intelligence (24 y) |
|           | Restricted | 2.4 y | 100–600 (2) | Abnormal (20.7 y) | Normal intelligence (24 y) |
| 5         | Normal | 3.0 m       | 1345 ± 661 (5) |             |     | Considered slow |
|           | Restricted | 6.0 m | 899 ± 129 (4) |             |     | Wechsler Intelligence Scale verbal 88, performance 84 (7.5 y) |
|           | Normal | 2.5 y | 909 ± 272 (3) | Normal (13 y) |     |          |
| 9         | Normal | 1.0 m       | 1217 ± 354 (2) |             |     | IQ 65 (11st percentile) (6 y) |
|           | Restricted | 1.2 y | 220 ± 176 (10) |             |     |          |
|           | Normal | 1.2 y | 87 ± 140 (5) | Normal (6 y) |     |          |
| 13        | Normal | 1.3 m       | 697 ± 87 (2) |             |     | Slow at school (16 y) |
|           | Restricted | 1.7 m | 193 ± 83 (4) |             |     |          |
|           | Normal | 10.0 y | 485 ± 49 (4) | Abnormal (8 y) |     |          |
| 20        | Normal | 1.5 m       | 1528 ± 85 (4) |             | Abnormal (0.1 y) |
|           | Restricted | 6.6 y | 684 ± 234 (14) | Normal (4.9 y) |     |          |
|           | Normal | 6.6 y | 1298 ± 112 (5) | Abnormal (10 y) |     |          |
### Table 3 Outcomes for treated patients (Continued)

| Patient No. | Birth | Age at Treatment | Treatment | Follow-up | Outcome |
|-------------|-------|------------------|-----------|-----------|---------|
| 30          | Normal Birth | 0.6 m | Restricted + betaine | 10.5 y | 0.6 m | 2.5 y | 400–1580 | Abnormal (3.8 y) | IQ 121 (3.5 y) |
| 31          | Normal Birth | 3 m | Restricted | 10.8 y | 1.8 y | Abnormal (0.8 y) | Development normal |
| 32          | Normal Birth | NA | Restricted | 1180 (1) | NA | 5.2 Y | 740–1150 | Abnormal (5 Y) | IQ 108 (9.4 y); neurologically normal |
| 43          | Normal Birth | 4 m | Normal | 1050 | 3 m | 1.8 y | 1025 ± 74 (2) | Abnormal (3 y) |
| 46          | Normal Birth | 1.5 m | Restricted | 928 ± 74 (8) | 4 y | 4.2 y | 994 (1) | Performance IQ 78; reasoning 57 (3.3 y) |
| 61          | Normal Birth | 735 | Restricted + betaine | 1105 ± 235 (2) | 2 w | 3.59 y | 700–1100 | Abnormal (3.5 and 4.5 y) | Normal |
| 62          | Normal Birth | < 5 m | Normal | 461 (1) | 1 y | 2.1 y | 860 ± 424 (3) | Developmental delay; autistic action (2.2 y) |
| 63          | Normal Birth | 1 m | Restricted | 570 (1) | 1 m | 1.2 y | 1159 (1) | Abnormal (1.5 y) | No neurological signs (2.9 y) |

**Patients treated with AdoMet supplementation only**

| Patient No. | Birth | Age at Treatment | Treatment | Follow-up | Outcome |
|-------------|-------|------------------|-----------|-----------|---------|
| 4           | Normal Birth | 11 y | AdoMet, 400 mg bid | 600–1400 (2) | 11 y | 12 y | Normal (12 y) | Headaches, nystagmus, dysdiadochokineses, increased tendon reflexes (11 y) |
| 22          | Normal Birth | 4.7 y | AdoMet, 400–800 mg bid | 1005–1676 (2) | 4.7 | 7.4 y | 1528 (1) | IQ improved to 69 (5.4 y); awake EEG markedly improved (6.3 y); IQ 64 (7.4 y) |
| 35          | Normal Birth | 3 m | AdoMet 100–200 mg bid | 1620 ± 107 (2) | 3 m | 1.2 y | 1159 (1) | Abnormal (1.2 y) |
| 50          | Normal Birth | <4.3 y | AdoMet, 400 mg bid | 878 ± 136 (3) | 4.4 y | 4.5 y | Normal (4.3 y) | Behavior considerably improved |
| 51          | Normal Birth | 3.3 y | AdoMet, 200 mg bid | 641 ± 74 (2) | 4.5 y | 4.9 y | Abnormal |
range of times. Details for each such patient are reported in Table 3 (see supplementary data), together with the mean plasma methionine concentrations before, during, and after restriction and very brief comments describing if and when MRI or clinical abnormalities were observed. For each patient with evidence of CNS abnormalities more detailed clinical histories and the reports of MRI findings are presented in Table 4 (see supplementary data). The pros and cons of using dietary restriction are described in more detail in the *Discussion* [sections 4.4.1 and 4.4.2].

AdoMet supplementation
AdoMet supplementation has been used for nine patients, each of whom had abnormal CNS findings. AdoMet was given during periods of methionine restriction in four of these nine patients. Summaries of these trials are listed in Table 3 with more details in Table 4. AdoMet supplementation is also discussed in the *Discussion* [section 5.2.1].

**Discussion**
Sufficient information has been gathered during the present survey to permit discussion of several important questions about MAT I/III deficiency:

**Diagnosis**
The possibility of MAT I/III deficiency usually arises with the finding of elevated plasma methionine without the marked elevations of tHcy that occur in CBS deficiency [50]. However, uncertainty may arise because, as shown in Fig. 4, MAT I/III deficient patients tend to have mild elevations of tHcy as their methionine levels rise. Assay of plasma AdoMet then becomes a useful next step, since plasma AdoMet is elevated in CBS deficiency (median 488 nM; 25–75 percentile, 155–868) [51], but is usually not elevated in samples from MAT I/III deficient individuals drawn at age of more that 3–4 months (Fig. 3). However, the few MAT I/III deficient patients among those under discussion who had early samples assayed for AdoMet often had very mild elevations of AdoMet (as high as 152 nM), and similar or slightly higher elevations (up to 220 nM) have been found in early samples from patients with one of the *MAT1A* mutations (e.g., R264H) that cause slight to moderate hypermethioninemia in heterozygotes. These rises do not persist beyond about age three months, and may perhaps be due to incomplete turning off of the expression of MAT II that occurs after birth. Thus, when investigating a child who at an early age has elevated methionine and, at most, slight elevations of tHcy and...
AdoMet, further evidence as to whether that child is a heterozygote, homozygote, or compound heterozygote for MAT1A mutation(s), may be obtained by assaying plasma methionine in both parents. If the child is a heterozygote for a dominant mutation one parent will also have at least a minimal elevation of plasma methionine. Strong evidence indicates that such heterozygotes will be clinically unaffected [30, 31]. If neither parent is hypermethioninemic, to pin down the diagnosis the MAT1A gene may be sequenced so that further monitoring and/or trials of therapy can take place if the child turns out to be a homozygote or compound heterozygote for MAT1A mutation(s).

Another finding is elevated cystathionine in samples of patients of young age, which may even be used as an additional marker to distinguish MATI/III deficiency from CBS deficiency [52]. Again, this elevation is transient and may probably be attributed to incomplete expression of cystathionine gamma-lyase, which activity is not expressed in fetal liver [53].

Liver function and hepatocellular carcinoma

MAT1A knocked out mice develop oxidative stress and nonalcoholic steatohepatitis by 8 months [54] and, a high incidence of hepatocellular carcinoma by 18 months [55]. Liver histology was studied in a few early MAT I/III-deficient patients who had liver biopsies performed to assay MAT activity before MAT1A genotyping became available. Light microscopy was usually normal (patients G1, G3 [17]; #2 [19]; #1 [14]; and #46 [15]), but electron microscopy showed a variety of abnormalities. Mitochondria were either normal (#2 [19]) or had breaks in their outer membranes (G1 [17]), or elongated (G2 [17]) or abnormal (#1 [14]) shapes. Smooth endoplasmic reticulum was increased in amount (G1 [17]; #2 [19]; and #46 [15]); rough endoplasmic reticulum, decreased (G1 [17]; #46 [15]). Increased pericellular collagen fibers were present in the space of Disse (G1; G2 [17]; and #46 [15]), and residual pigment in lysosomes of two patient (G3; G4 [17]). Together, these findings raise concern about liver function in MAT I/III-deficient patients. To date hepatocellular carcinoma has not been found in any of the patients under discussion. Although most are still relatively young, at last report patient #2 was 60, four patients were ages 32 to 40; and nine were in their twenties. Taken together with the fact that the liver function tests in the 30/64 patients so investigated were normal (including several (G1, G2, G4, #2, #46) who had hepatic electron microscopic changes (data not shown in Tables), these results are encouraging with regard to liver function and the chances of developing hepatic malignancies.

Pregnancy outcomes

The fact that five of the patients produced eight normal babies from nine pregnancies is encouraging. However, one patient had only two normal babies as a result of six pregnancies. Further experience will be needed to fully evaluate the effects of maternal MAT I/III-deficiency on pregnancy.

CNS abnormalities

Of the 64 patients under discussion, 32 have been classified as not having evidence of CNS abnormalities, whereas 32 have been classified as having such evidence. It should be noted, however, that whether a given patient is assigned to the group of those without or with CNS problems is subject to several limitations: (a) several of the patients without evidence of CNS abnormalities are, as yet, very young (see Table 1 and Fig. 2). CNS problems may arise as they age. (b) The classification is based most often upon the reported presence of MRI abnormalities, and there may be some ascertainment bias with regard to carrying out MRI studies. Although the majority of patients in both groups were ascertained by screening of newborns or family members (31/32 and 27/32, respectively), among those without evidence of CNS abnormalities MRIs were done on only 6/32 and were in all cases normal, whereas among those classified as having CNS abnormalities 28/32 had MRI studies with 4 being normal. In the rest 24 being abnormal, 5 became normal and 2 reported as improving. Thus it is possible that had more of the group without evidence of CNS abnormalities had MRIs, more abnormalities would have been found. (c) The grounds for classifying a few of the patients as having CNS abnormalities may be weak or not even causally related to MAT I/III deficiency. The most questionable cases are patient 5 who was considered slow at learning and had Wechsler Intelligence Scale scores of verbal 86 and performance 84; patient 13 who was slow at school; and, perhaps, patient 9 who had an IQ of 65 (1st percentile). In spite of these limitations, as already mentioned in the “Results” section, the scatter diagram of patients with and without CNS abnormalities against their mean plasma methionines (Fig. 2) suggests stratification: those without CNS problems usually have methionines below 800 μM; those with CNS problems have plasma methionines of 800 to almost 1500 μM.

Has dietary methionine restriction, the treatment most often used, been harmful?

There is concern that, if some residual MAT I/III activity is still present, lowering methionine concentrations might further limit the flux due to that residual activity, as well as the flux through MAT II, thereby further decreasing the availability of AdoMet and aggravating the possibility of developing CNS problems [50]. The present
Table 4 Histories of patient with possible abnormal CNS findings (Continued)

observed in the white matter [37]. At age 7 y the delay of myelination had disappeared [41].

Patient 31: This sib of #30 was on dietary methionine restriction from age 3 months to 1.8 years. An MRI at 0.8 y showed delayed myelination of white matter with T1 and T2 prolongation in the symmetric tegmental tract. At 3 y his development was normal and neurological examination unremarkable, but MRI showed delayed myelination in white matter with symmetric lesions in the dorsal brain stem [41].

Patient 32: Patient 32 was on methionine restriction from an early age. An MRI at 5 y showed delayed myelination equivalent to that in normal children’s at age 6 months. Methionine restriction was discontinued. An MRI at age 5.5 y was unchanged [36]. At age 9.4 y his IQ was 108, physical and neurological examinations were normal, but myelination was the same as that at 5.5 y.

Patient 34: This child of consanguineous parents had a large head, facial dysmorphia, severely retarded, slow and infrequent movements of the body, head and eyes with suspected central visual impairment. After start of methionine restriction and AdoMet supplementation at about 5.5 months of age, he was said by age 8.3 months to have improved, but details are not available.

Patient 35: An MRI performed at age at 1.2 y because MAT-I/II deficiency with severe hypermethioninemia had been established, showed bilaterally symmetrical restricted diffusion in the commissural fibers of the corpus callosum, anterior commissure, internal capsule, and globus pallidus. Spectroscopy demonstrated a diminished NAA peak. MRI at 1.8 y after 6 months of AdoMet administration, showed improvement in areas of restricted diffusion in the corpus callosum, anterior commissure, globi pallidi, and white matter. The right anterior commissure was the only area where restricted diffusion was possibly slightly increased.

Patient 36. This identical twin of patient 37, was born prematurely at 32 weeks gestation. At age 2.3 y each twin had developmental delays, especially of speech, but an MRI of brain of one twin was normal.

Patient 37: See identical twin, patient 36.

Patient 38: This daughter of consanguineous parents and sib of patient 39 who was noted at age 3 y to have developmental delay. At age 5 y she had myoclonic epilepsy treated with valproic acid. At age 11.1 y she was perfectly healthy apart from learning difficulties for which she was in a special class at grade 2 level. At age 12.8 y she was in 4th grade rather than 7th. An MRI showed prolonged relaxation time and shortened apparent diffusion coefficient.

Patient 39: An MRI at 5.2 y showed: prolonged relaxation time, and shortened apparent diffusion coefficient in this boy. At age 10.5 y he was in 3rd grade rather than 5th, but otherwise well.

Patient 41: An MRI at 0.24 y showed: abnormal symmetric T2 hyperintensity along the cortical spinal tract from the perirlandic white matter through the centrum semiovale, post limb internal capsule, cerebral peduncles, anterior pons and medulla. Also present were symmetric abnormal signal within the dorsal brainstem tegmental tract, extending into the cerebellum and along the hippocampal formations and within the fornix. Within these areas there was restricted diffusion and diffuse swelling. The patient was started on methionine restriction which has continued to present. AdoMet supplementation was started at age 6.7 y. An MRI at 7.1 y was normal and the parents think AdoMet has been very helpful.

Patient 42: An MRI of this boy at 1.2 y showed bilateral symmetrical areas of hyperintense T2-weighted images in white matter at the level of temporal-insular and temporal-mesial, deep paretal, ponto-mesencephalic dorsal and cerebral peduncles with involvement of the structures above and the capsular lenticular corpus callosum. ADC values were reduced to diffusion. At age 1.5 y he was noted to have speech delay.

Patient 43: This boy was on methionine restriction from age 0.8–3.2 y. At 3.3 y a neuropsychological evaluation found a developmental age of
Table 4 Histories of patient with possible abnormal CNS findings (Continued)

| Patient 45: At age 4 y physical and neurological examinations and physiotherapeutic testing of patient 45 were normal, but an MRI showed white matter changes and delayed myelination. At age 4.1 y she started protein restriction and supplemental AdoMet. At age 4.5 y physical and neurological examinations and physiotherapeutic testing continued to be normal. An MRI showed normal white matter and delayed myelination. |
| Patient 46: This woman was on methionine restriction from age 0.1–4.0 y, then on a normal diet. Her IQ by WISC-R at age 9 y was 99 [15, 46]. An MRI at age 30 y showed T1 and T2 prolongation in the deep white matter, but physical and mental development have been entirely normal. |
| Patient 47: A dietary history is not available for this patient. At age 9 y she had dysdiadochokinesia and MRI showed hypomyelination. At age 10 she had normal cognition and an MRI at 17 y was almost normal. |
| Patient 50: An MRI of patient 50 at 4.3 y showed: white matter changes, in particular restricted diffusion in the area of the genu of the corpus callosum. There were no changes in T1 or T2. Supplementation with AdoMet, 200 mg/d was started at age 4.4 y and the dose increased to 400 mg/d at 4.5 y. The patient’s behavior with regard to aggression and hyperactivity were improved at 4.9 y. |
| Patient 51: The behavior of this younger sister of patient 50 deteriorated by age 3.7 y and supplementation with AdoMet was started at 200 mg/d. Outcome not know to date. |
| Patient 56: This woman was ascertained and genotyped at age 38 y as a result of having given birth to two children with transient hypermethioninemia on newborn screening. She had never been on methionine restriction. She received average grades throughout school and has an associate degree. She has had hand tremors since childhood and is affected with depression. Physical examination showed increased deep tendon reflexes, tremors, dysmetria and dysdiadochokinesis. |
| Patient 60: Despite her normal development until age 1.4 y, an MRI showed extensive abnormal signal in the white matter of the corpus callosum and of the anterior commissure. Neuroimaging at age 2 years showed similar results [40]. At age 5.6 y she showed possible mild neuropsychic delay and hyperreflexia. |
| Patient 61: At early age (3 weeks) this boy was treated with methionine restriction and betaine because of mild hyperhomocysteinemia. At age 2.5 y pyridoxine was added. Treatment was discontinued at age 3.9 y. Brain demyelination was revealed at age 3.5 y and confirmed at 4.5 y. At age 5.5 no neurological symptoms were reported. |
| Patient 62: At age 2.1 years developmental delay and autistic action of this boy led to the start of dietary methionine restriction. An MRI at age 2.3 y was normal and the diet was discontinued at age 2.4 y. IQ is 108 at age 3.3 y. At age 4.3 y the boy was developing normally and attending kindergarten. |
| Patient 63: At age 10 months an MRI of patient 63 showed diffuse abnormal lesions in the white matter indicative of delayed myelination. T2-weighted images showed no myelination in the external capsules or anterior limbs of the internal capsules, but lack of T1-weighted images made evaluation difficult. At 18 months the abnormal lesions in the white matter were more extensive. However, at age 2.9 y, there were no neurological signs. |

study produced results for eight patients, each of whom has had some period of methionine restriction, who remained free of evidence of CNS abnormalities (see first section of Table 3). Five of these had only missense mutations; patient 48 had one missense and one truncating mutation; patient 58 was not sequenced. The methionine restriction used for these individuals did no apparent harm. Patient 13 is one in whom restriction may possibly have had adverse effects. Although his methionine on normal diets at ages was 485 μM, after methionine restriction from age 1.7 to 10 months with a mean level of 193 μM he was found at age 8 to have an abnormal MRI and was judged to be slow at school.

Has methionine restriction been beneficial?

Evidence as to the usefulness of methionine restriction is limited and prevents drawing any firm conclusions. Findings that might be considered strongly convincing of benefit would be for example an individual with methionine values of > 900 μM at ≥ 5 months on normal diets, who after using a methionine restricted diet remained free of CNS abnormalities, but such informative cases are not available. For the eight patients without evidence of CNS abnormalities who had been on dietary restriction (Table 3), mean methionine values on normal diets at ages ≥ 5 months ranged from 175 to 777 μM (mean 388 ± 208), so there is a likelihood that they would not have had CNS abnormalities even if they had not been on methionine restriction. The findings for several patients, however, are at least suggestive of benefit: patient 20 remained normal until age 5.4 years while on methionine restriction that kept his methionine down to 684 μM, but developed MRI abnormalities after diet was discontinued and methionine climbed to 1298 μM. Patient 1 (during) and patient 46 (after) methionine restriction are normally intelligent at ages 20.7 and 34 years, although each has MRI abnormalities. Patient 13 developed abnormalities after stopping methionine restriction. Patient 62’s behavior improved on restriction and patient 63’s MRI worsened after stopping restriction.

Pathophysiology

As just detailed, judged by the data on outcomes, the evidence available as to optimal treatment of the patients in question is unclear. An alternative means to try to find the optimal treatment might be to consider the pathophysiology of the metabolic abnormalities in MAT I/III deficiency. There is strong evidence of stratification between the presence or absence of CNS problems and mean methionine concentrations. This could indicate toxicity of very high methionine concentrations itself, deficiency of AdoMet due to more severe loss of MAT I/III activity, the rise in tHcy, or some combination of more than one of these factors. Details of each of these alternatives are discussed below.
Fig. 1 Mean plasma methionine values of untreated patients in the first months of life are plotted against mean ages at which samples were drawn. Red markers indicate patients with evidence of CNS abnormalities; green markers, patients without such evidence.

Fig. 2 Plasma methionine concentrations for patients on normal diets without (green) or with (red) evidence of CNS abnormalities. Green values are plotted against age at last report; red values, against age at which CNS abnormality was first found. Triangles indicate mean methionine values at ages ≥ 5 months; circles indicate mean methionine values at ages < 5 months (if values at older ages are not available; and plotted against age at last report).
Methionine elevation

High plasma methionine and brain edema

The MAT I/III deficient patient of Tada et al. (#30) developed brain edema while on betaine (and B6) treatment resulting in methionine concentrations between 960 and 1560 μM [36]. Braverman et al. [52] reviewed four cases with edema and severe elevations of plasma methionine. Brain edema developed in two CBS deficient patients on betaine with methionine of 1190 and 3000 μM. Because betaine is also an intracellular osmolyte, its high levels may have contributed to the development of edema. In the same report Braverman et al. reviewed two normal infants having edema after an extreme high methionine intake resulting in plasma methionines of 2154 and 6830 μM.

Taken together very severe elevations of methionine (above 2000 μM) may induce edema, whereas the use of betaine may already lead to edema if plasma methionine is above 1000 μM. Although edema is only reported in patients with MAT I/III deficiency if using betaine, it can not be ruled out that a more subtle inability of cells to pump water adequately may contribute to CNS problems.

Might methionine inhibit some methyltransferase activity necessary for myelination or another vital CNS function?

Methyl transfer reactions definitely occur in brain [56], but their quantitative extent has not been established. A review of the literature turned up no instances of methionine inhibition of an AdoMet-dependent methyl transfer reaction.

Might some break-down product of methionine play a role in CNS problems?

Dever and Elfarra [57] pointed out that products of the methionine transamination pathway and/or sulfoxidation should be considered as a potential cause of CNS problems. It is well established that patients with methionine elevations now known to be due to MAT I/III deficiency utilize transamination when plasma methionine is above about 350 μM [58]. Evidence on transamination or
sulfoxidation products has not been collected during the present survey. We do know that Patient 2, a homozygote for a truncating mutation, presented with bad breath odor due to dimethylsulfide formed by the transamination pathway [20], but that he remains clinically well at age 60 years. Another argument against the transamination and/or sulfoxidation products hypothesis is that it would not explain the beneficial effect of AdoMet supplementation, for which there is relatively strong evidence (as mentioned in sections 5.1.5 and 5.2.1).

**Might very high methionine compete for transport of other amino acids across the blood–brain-barrier so severely as to cause damage?**

Methionine is transported across the blood–brain-barrier by the “large neutral amino acid” (LNAA) system, as are nine other amino acids. Phenylalanine has the lowest Km, 11 μM, for this system; methionine is the fourth lowest, 40 μM [59]. The system normally functions near saturation with LNAA’s, so that if one of them rises above its normal plasma level, to some extent, it will compete with the other LNAA’s and inhibit their transport across the blood–brain-barrier [59]. One hypothesis to explain the CNS damage of phenylketonuria (PKU) is that competition by phenylalanine for LNAA transport accounts for the adverse effects [60]. Until recently there was an international consensus that phenylalanine levels of < 360 μM are not harmful and do not need treatment. More recent evidence has shown that even phenylalanine levels of as high as 800 μM are either clinically benign [61], or lead only to MRI changes of uncertain significance [62]. Because the Km of methionine for the LNAA transporter is 40/11 = 3.6-fold higher than that of phenylalanine, it seems that the extent of competitive inhibition of LNAA uptake by methionine concentrations of as much as 3.6 × 360 μM = 1296 μM are unlikely to
be harmful, whereas concentrations above 1296 μM and up to 3.6 × 800 = 2880 μM might bring about MRI changes.

**Might high plasma methionine inhibit the transport of AdoMet into brain?**

Chishty et al. describe the carrier mediated transport of AdoMet to the blood–brain barrier by system(s) that transport adenosine, but not methionine [63]. Therefore, it seems unlikely that methionine interferes with transport of AdoMet across the blood–brain barrier. CSF AdoMet concentrations without AdoMet supplementation are available for three patients, each of whom had CNS problems: two, patient 4 [64] and patient 29 [44], had somewhat low levels; one (patient 43) had a normal level. It is noteworthy that the concentration of AdoMet in CSF may not accurately reflect the brain tissue concentration. For example, there was no significant relationship between AdoMet concentrations in CSF and those in brain after treatment of pigs with nitrous oxide which dramatically changed the AdoMet/AdoHcy ratio [65]. Metz also discussed this discrepancy in his review article [66]. In spite of these limitations, it appears that there is no strong evidence that high plasma methionine interferes with delivery of AdoMet from plasma to brain.

**Might very high methionine somehow decrease the AdoMet concentration of the brain?**

One possibility is that methionine inhibits MAT II activity. However, studies of the kinetic properties of MAT II do not mention methionine inhibition of this activity [67], even when brain MAT II was studied [68]. Another possibility is that high methionine might lead to decreases in the amount, rather than the activity, of MAT II. Such an effect has been reported in both human hepatoma [69] and neuroblastoma cells [70], but not in H35 or cos7 cells [71]. However the effect in hepatoma cells depended upon synthesis of AdoMet, so it seems unlikely to occur in brain in cases of MAT I/III deficiency. Direct evidence of the effect of high methionine on brain AdoMet concentrations has been reported by Young and Shalchi, who assayed AdoMet in rat brains after administration of increasing doses of methionine and found a tendency for brain AdoMet concentrations to decrease with the higher doses of methionine [72]. If the brain AdoMet levels in the MAT I/III-deficient patients follow the tendency reported by Young and Shalchi to decrease in the presence of especially high methionine, and fall below normal with the highest plasma methionines (a proposition that needs to be tested, at least on experimental animals) it would then be plausible to suggest that the CNS problems of MAT I/III deficiency with the higher elevations of methionine are due in part to lack of AdoMet. Such a suggestion, if correct, would provide not only an explanation of the CNS pathology, but also indicate why supplementation with AdoMet might be helpful.

**MAT I/III activity**

*Is there a relationship between the severity of loss of MAT I/III activity and the presence of CNS problems?*

No such relationship is clearly established. Determination of the MATIA genotype for a given patient does not provide a firm basis on which to judge the likelihood of CNS damage. A patient homozygous for truncating mutations that presumably leave no residual MAT I/III activity do not have CNS problems (e.g., Patient #2). Several compound heterozygotes with mutations that, when expressed individually in *E. coli*, have at least some residual activities [25–27, 34] do have CNS problems (e.g., patients 5, 9, 13, 20, 30, 31, 36, 37, 38, 39, 46, 60). One possibility is that more severe loss of MAT I/III activity and the resulting decrease in the rate of synthesis of AdoMet might lead to lowering the level of plasma AdoMet, thereby decreasing delivery of AdoMet from plasma to brain. However Fig. 3 shows that there is no trend for those with higher plasma methionines to have lower plasma AdoMet concentrations. Presumably plasma AdoMet is sustained at normal (93 ± 16 nM) or close to normal by MAT II activity even when MAT I/III activity is low or negligible (note that MAT II expression and protein are increased three-fold in MATIA KO mice [54]). Figure 3 provides strong evidence that the CNS damage is not the result of differential delivery from plasma to brain at the concentrations that occur without AdoMet supplementation. It does not rule out the possibility that at higher concentrations of AdoMet resulting from supplementation, there might still be a therapeutic increase in the delivery of AdoMet to brain. Orally administered AdoMet has been shown to raise the plasma [73, 74] and the CSF [74] concentration of AdoMet. Because in most cases AdoMet supplementation has had positive therapeutic effects (Table 3), this method of therapy is supported by the available evidence.

**Does loss of hepatic MAT I/III activity impair the synthesis, and subsequent delivery from liver to brain of one or more compound(s) important in CNS function?**

This possibility was considered previously for creatine and choline, formed in liver by the AdoMet-dependent guanidinoacetate and phosphatidylethanolamine methyltransferases [75], and appeared to be supported when early genetic studies found that two patients with brain demyelination were homozygotes for truncating MATIA mutations that led to complete loss of MAT I/III activity [26]. However, the subsequent finding of a homozygous MATIA mutation in a clinically well older patient (Patient #2) weakened the hypothesis in question and the data in Table 1 showing a lack of correlation
between complete loss of activity and CNS problems further weaken it.

Another possibility related to decreased flux through phosphatidylethanolamine methyltransferase is that such decreases lead to CNS damage that may be prevented by docosahexaenoic acid (DHA) [76], a compound important in normal brain development and one the dietary intake of which is highly variable [77]. The intakes of DHA, and/or sources of choline, and creatine at crucial periods during growth, may therefore have played roles in the presence or absence of CNS problems in the MAT I/III patients. Variability in the CNS status of the three patients homozygous for R199C (patients 10, 11, and 13) might possibly be an example of effects of such factors (see, also the discussion [78]).

**Does MAT I/III activity in brain contribute so significantly to the CNS need for AdoMet that more severe losses lead to the CNS problems?**

Reytor et al. have shown that MATIA is expressed in brain [12] but the expression in brain is very low (perhaps 0.2 %) of that in liver. It remains unclear what the total requirement of brain for AdoMet is, or the extent to which that requirement is met by MAT II. There is also the possibility that expressed MATIA product affects nuclear localization or plays a role in, for example, specialized histone methylations [12], so a definitive answer to the question of the role of MATIA expression in brain is not available.

**Do the increased levels of tHcy lead to the CNS problem?**

As shown in Fig. 4, and consistent with previous observations [49], tHcy tends to rise as methionine increases. However, there is no striking elevation of the tHcy values for those with CNS problems above the tHcy values for those without CNS problems. Furthermore the tHcy levels are not higher than the values found in treated cystathionine β-synthase (CBS) deficient patients who have essentially normal IQ’s [79].

**Summary conclusions and tentative suggestions for management**

No definitive answer to the question of what is the best strategy for management of severe MAT I/III deficiency emerges from consideration of either the available evidence on treatment outcomes or the numerous pathophysiologic mechanisms through which either loss of MAT I/III activity, methionine elevation, or some combination of both might lead to CNS problems. Given these given, we suggest here what seem at this time to be reasonable, although tentative, management guidelines:

In an asymptomatic, well looking newborn of normal birthweight and gestational age with persistent hypermethioninemia and plasma tHcy higher than, perhaps 100 μM, CBS deficiency becomes the presumptive diagnosis. If, at most, plasma tHcy is elevated to perhaps 50–60 μM, the diagnosis is less clear. Determining the concentrations of AdoMet and AdoHcy in plasma of the patient, and, if possible, methionine in both parents will further pin-point the defect. To rule out CBS deficiency one may also determine cystathionine but this requires a suitably sensitive assay available in only a few specialized laboratories” [51]. Determination of the CBS activity in cultured fibroblasts and sequencing of the CBS gene will provide a final diagnosis. In the differential diagnosis of hypermethioninemia also deficiencies of S-adenosylhomocysteine hydrolase, adenosine kinase and glycine N-methyltransferase need to be mentioned. These inborn errors of methionine metabolism may also show elevated tHcy. The determination of AdoMet and AdoHcy is most helpful in pinpointing the potential defect. Secondary causes of hypermethioninemia include liver disease, tyrosinemia type I, galactosemia and citrin deficiency.

The majority of newborns now being flagged for methionine elevations in screening programs with lowered methionine cut-off values are turning out to be heterozygotes for one of the MATIA mutations now known to cause mild to moderate hypermethioninemia. This heterozygosity will almost surely cause no adverse long-range clinical effects. If neither parent has a mild methionine elevation, and a sample up to three months has no more than a slightly high concentration of AdoMet at a time the methionine remains high, a diagnosis of homozygous or compound heterozygous MAT I/III deficiency is strongly indicated. Sequencing of the MATIA gene will help to make the diagnosis more specific and secure. While these steps are being taken, the newborn might be monitored by assay of plasma methionine at about 1 month intervals. If that mean is above perhaps 500–600 μM, dietary methionine restriction should be considered, strict enough to maintain a methionine concentration near that level, but not a great deal below it. In patients with Mudd disease methionine levels may vary wide in the first months of life making the decision on methionine restriction not straightforward in this period. If possible this decision can better be made after the first months of life. If the mean plasma methionine is below 500 μM it seems likely that dietary restriction is not indicated.

Whether on methionine restriction or not, an eye should be kept out for development of CNS abnormalities and, if indicated, brain MRI performed. If problems arise while on a normal diet, starting or restarting methionine restriction or AdoMet supplementation may be considered. If problems develop while on restriction, supplementation with AdoMet should be considered. The available evidence suggests that AdoMet supplementation may lead to normalization of even MRI changes that have already occurred.
It is important to emphasize, again, that the stratification into those with or without evidence of CNS abnormalities, upon which the above suggestions rely to provide guidance, may be affected by ascertainment bias, and that the management guidelines put forth here are tentative and will need to be reevaluated and perhaps modified as experience with MAT I/III deficiency is extended.

**Abbreviations**

MAT: Methionine adenosyltransferase; CNS: Central nervous system; AdoMet: S-adenosylmethionine; AdoHcy: S-adenosylhomocysteine; CBS: Cystathionine beta-synthase; LMNA: Large neutral amino acid system; Hcy: Total homocysteine in plasma; NBS: Newborn screening.

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contributions**

YHC, JA, FB, AAB, FC, MD, CF, CF, DF, GG, KH, FH, GH, WHL, PJ, SK, SHK, RL, HL, ML, LL, EM, AM, YO, KR, ERG, SSB, AS, RS, MS, JT, WGW, SW, SY and HJB provided information about the patients, contributed to the interpretation of the data and revised draft manuscripts. S Harvey Mudd initiated, coordinated and executed the study and wrote the first versions of the manuscript, supported by YHC. CW and ST performed biochemical analyses and supported in writing and revising the manuscript. After SHM passed away unexpectedly, HJB took over coordination of this study on behalf of Dr Maryland Pao, Clinical and Deputy Scientific Director, NIMH, supervisor and colleague of S Harvey Mudd. HJB and YHC prepared the final version of this manuscript, which was read and approved by all authors.

**Acknowledgement**

This manuscript was made possible through the unwavering dedication of the late Dr. Harvey Mudd, who devoted over fifty years of his scientific career to advancing the understanding of hypermethioninemia. Undoubtedly the world’s expert on the disorder, Dr. Mudd served as the focal point to a vast network of scientists and clinicians who regularly sought his expert consultation. His rigorous attention to maintaining case histories, lab results and precise documentation from these consultations yielded a rich collection of legacy data on this rare disorder. As his closest colleagues understood, he wanted nothing more than to have this important information published and shared in the scientific community. Use of this legacy data by the authors was approved by the Office of Human Subjects Research (OHSR) at the NIH under current human subjects regulations recognizing Dr. Mudd’s outstanding contributions.

We like to thank the many physicians who participated in the management of these patients or in studies of their metabolic abnormalities, and the patient’s families for their care and consideration. We would like to acknowledge Maryland Pao for her strong support, in particular her contribution to finalize this manuscript.

This research was supported in part by National Institute of Mental Health Intramural Research Program and the E-HOD project (No.2012_12_02) of the European Union in the framework of the Health Program. The opinions in the article are the views of the authors and do not necessarily reflect the views of the Department of Health and Human Services or the United States government.

**Author details**

1. Department of Medical Genetics and Pediatrics, National Taiwan University Hospital, Children’s Hospital Building, Taipei, Taiwan.
2. Division of Metabolic Disorders, CHOC Children’s, Orange, CA, USA.
3. Newborn Screening and Inborn Errors of Metabolism Regional Centre, Paediatric Endocrinology Program, Paediatric Unit, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
4. Children’s Hospital of Michigan Metabolic Clinic, Detroit, MI, USA.
5. Department of Hepatology, Proteomics laboratory, Center for Applied Medical Research (CIMA), University of Navarra, IdiSNA, Pamplona, Spain.
6. Head of Metabolic Unit, Department Pediatrics, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
7. Department of Gastroenterology, Hepatology and Infectious Diseases, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
8. The Children’s Hospital of Philadelphia, Division of Metabolism, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
9. Department of Pediatrics, University of Colorado, Aurora, CO, USA.
10. Department of Clinical Sciences, Pediatrics Umeå University, SE 901 85 Umeå, Sweden.
11. Department of Pediatrics, Division of Genetics and Metabolism; Department of Internal Medicine, Division of Clinical Genetics, and McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX, USA.
12. Department of Pediatrics, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto, Japan.
13. Division of Paediatrics, Department of Metabolic Diseases, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands.
14. Department of Paediatrics, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA.
15. Children’s Hospital Boston, Harvard Medical School, Boston, USA.
16. KSZ Children’s Hospital/Korea Genetics Research Center, Jikjidoar, Heung Duck Gu, Cheng Ju City, Chung BUK, Republic of Korea.
17. Division of Genetics and Department of Metabolic Diseases, Hebrew University, Hadassah Medical Center, Jerusalem, Israel.
18. Charles Dent Metabolic Unit; National Hospital for Neurology and Neurosurgery, London, UK.
19. Department of General Pediatrics, Division of Pediatric Metabolic Medicine and Neuropsychiatry, University Hospital Heidelberg, Heidelberg, Germany.
20. Department of Neurology, University Children’s Hospital Frankfurt, Frankfurt, Germany.
21. First Department of Pediatrics, University of Athens, Agia Sofia Children’s Hospital, Athens, Greece.
22. Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children’s Hospital Dusseldorf, Dusseldorf, Germany.
23. University Children’s Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
24. Department of Genetics, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Japan.
25. Department of Medicine and Pathology, Biochemical Genetics Laboratory, Mayo Clinic College of Medicine, Rochester, MN, USA.
26. Department of Pediatrics and Laboratory Genetic Metabolic Diseases, Maastricht University Medical Center, Maastricht, Netherlands.
27. Medical University of Innsbruck, Clinic for Pediatrics, Inherited Metabolic Disorders, Innsbruck, Austria.
28. Genetica and Genome Biology, Peter Gilgan Center for Research and Learning The Hospital for Sick Children, Toronto, ON, Canada.
29. Department of Human Genetics and Pediatric, Emory University, Atlanta, GA, USA.
30. Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
31. Department of Medical and Molecular Genetics Indiana University School of Medicine, Indianapolis, IN, USA.
32. Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN, USA.
33. Division of Genetics, University of Virginia School of Medicine, Charlottesville, VA, USA.
34. Nijmegen Centre for Mitochondrial Disorders (NCMD), RadboudUMC, Amalia Children’s Hospital, Nijmegen, The Netherlands.
35. Department of Pediatrics, National Shimoshizu Hospital, Chiba, Japan.
36. Laboratory of Molecular Biology, National Institute of Mental Health, Bethesda, MD, USA.
37. Laboratory for Clinical Biochemistry and Metabolism, Center for Pediatrics and Adolescent Medicine University Hospital Freiburg, 79106 Freiburg, Germany.

**Received: 8 April 2015 Accepted: 13 August 2015**

**Published online: 20 August 2015**

**References**

1. Cantoni GL. Activation of methionine for transmethylation. J Biol Chem. 1951;189:745–54.
2. Catoni GL. S-Adenosylmethionine, a new intermediate formed enzymatically from L-methionine and adenosinephosphates. J Biol Chem. 1935;204:93–16.
3. Petrocini TC, Clarke SG. Discovering the human methyltransferosome. Mol Cell Proteomics. 2011;10(M110)000976.
4. Tabor CW, Tabor H. Polyamines Annu Rev Biochem. 1986;53:749–90.
5. Fontecave M, Atta M, Mullié E. S-adenosylmethionine: nothing goes to waste. Trends Biochem Sci. 2004;29:243–9.
6. Finkelstein JD. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin Chim Acta. 2007;375:1694–9.
7. Atala AM, Corrals FJ, Lozano MA, Sadelain M, Martínez J, et al. A control switch that regulates liver function. FASEB J. 2002;16:15–26.
8. Frey PA, Hegeman AD, Ruzicka FJ. The Radical SAM Superfamily. Crit Rev Biochem Mol Biol. 2004;39:63–88.
9. Sanchez-Perez GF, Bautista JM, Pajaes MA. Methionine adenosyltransferase as a useful molecular systematics tool revealed by phylogenetic and structural analyses. J Mol Biol. 2004;335:593–706.
10. Kotb M, Mudd SH, Mato JM, Geller AM, Kredich NM, Chou JY, et al. Consensus nomenclature for the mammalian methionine adenosyltransferase genes and gene products. Trends Genet. 1997;13:51–2.

11. Lu SC, Gukovsky I, Lugea A, Reyes CN, Huang ZZ, Chen L, et al. Role of S-adenosylmethionine in two experimental models of pancreatitis. FASEB J. 2003;17:56–8.

12. Reytor E, Perez-Miguelsanz J, Alvarez L, Perez-Sala D, Pajares MA. Conformational signals in the C-terminal domain of methionine adenosyltransferase III determine its nucleocytoplasmic distribution. FASEB J. 2009;23:3347–60.

13. Gaul GE, Talian HH. Methionine adenosyltransferase deficiency: new enzymatic defect associated with hypermethioninemia. Science. 1974;186:59–70.

14. Gout JP, Serre JC, Dieten M, Antener I, Frappat P, Bost M, et al. Still another cause of hypermethioninemia in children: S-adenosylmethionine synthetase deficiency. Arch Fr Pediatr. 1973;44:416–23.

15. Hase Y, Sawada Y, Tsuruara T, Kobayashi Y, Ohtake H, Miyagi T, et al. Hypermethioninemia associated with hepatic methionine adenosyltransferase deficiency: report of two cases. Pediatrics International. 1984;26:565–71.

16. Finkelstein JD, Kyle WE, Martin JJ. Abnormal methionine adenosyltransferase in hypermethioninemia. Biochem Biophys Res Commun. 1976;66:1491–7.

17. Gaul GE, Talian HH, Lonsdale D, Pzryzembel H, Schaffner F, von Baswietz DB. Hypermethioninemia associated with methionine adenosyltransferase deficiency: clinical, morphologic, and biochemical observations on four patients. J Pediatr. 1981;98:734–41.

18. Hase Y. Needed after translation. Bulletin on Special Formula. 1983;7:15–21.

19. Gaul WA, Finkelstein JD, Mullen KD, Bernardini I, Martin JJ, Backlund P, et al. Hepatic methionine adenosyltransferase deficiency in a 31-year-old man. Am J Hum Genet. 1978;40:39–49.

20. Gaul WA, Bernardini I, Finkelstein JD, Tangerman A, Martin JJ, Blom HJ, et al. Transsulfuration in an adult with hepatic methionine adenosyltransferase deficiency. J Clin Invest. 1988;81:390–7.

21. Talian HH, Cohen PA. Methionine adenosyltransferase activity: kinetic properties of human and rat liver enzymes. Biochem Med. 1976;16:234–40.

22. Horikawa S, Ishikawa M, Ozasa H, Tsukada K. Isolation of a cDNA encoding the rat liver S-adenosylmethionine synthetase. Eur J Biochem. 1989;184:497–501.

23. Alvarez L, Arucin M, Corrales F, Pajares MA, Mato JM. Analysis of the 5′ non-coding region of rat liver S-adenosylmethionine synthetase mRNA and comparison of the Mr deduced from the cDNA sequence and the purified enzyme. FEBS Lett. 1991;290:142–6.

24. Sakata SF, Shelly LL, Ruppert S, Schutz G, Chou JY. Cloning and expression of murine S-adenosylmethionine synthetase. J Biol Chem. 1993;268:13798–86.

25. Ubagai T, Lei KJ, Huang S, Mudd SH, Levy HL, Chou JY. Molecular mechanisms of an inborn error of methionine pathway. Methionine adenosyltransferase deficiency. J Clin Invest. 1995;96:1943–7.

26. Chamberlin ME, Ubagai T, Mudd SH, Wilson WG, Leonard JV, Chou JY. Demyelination of the brain is associated with methionine adenosyltransferase I/III deficiency. J Clin Invest. 1996;98:1021–7.

27. Chamberlin ME, Ubagai T, Mudd SH, Thomas J, Pao YW, Nguyen TK, et al. Methionine adenosyltransferase I/III deficiency: novel mutations and clinical variations. Am J Hum Genet. 2000;66:347–55.

28. Chien YH, Chang SC, Huang A, Hwu WL. Spectrum of hypermethioninemia in Taiwan Japanese. J Inherit Metab Dis. 2007;30:214–5.

29. Ito M, Kotani Y, Matsuda J, Chihri Y, Naito E, Morii K, et al. A methionine adenosyltransferase (MAT) deficiency patient treated with diet therapy. J Inherit Metab Dis. 2003;26:76.

30. Lagler F, Muntau AC, Bilbo S, Rötshinger W, Linnebank M, Fowler B, et al. Hypermethioninemia and hyperhomocysteinemia in methionine adenosyltransferase I/III deficiency. J Inherit Metab Dis. 2000;23:368.

31. Zeisel SH. Choline: essential for brain development and function. Adv Pediatr. 1997;44:263–95.

32. Mudd SH, Tangerman A, Stabler SP, Allen RH, Wagner C, Zeisel SH, et al. Maternal methionine adenosyltransferase I/III deficiency: reproductive outcomes in a woman with four pregnancies. J Inherit Metab Dis. 2003;26:443–58.

33. Landau YE, Levy HL, James PM. Transient neonatal hypermethioninemia in maternal MAT I/III deficiency. Mol Genet Metab. 2012;102:298.

34. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2011. p. 2007.

35. Stabler SP, Meadow C, Wolfszdo, Jaekus JA, Kraus JP, Allen RH, et al. Elevated plasma total homocysteine in severe methionine adenosyltransferase I/III deficiency. Metabolism. 2002;51:881–8.

36. Mudd SH. Hypermethioninemias of genetic and non-genetic origin: A review. J Med Genet. 2001;38:247–51.

37. Fernández-Iturroz J, Santamaría E, Chien YH, Hwu WL, Kormann SH, Faghfoury H, et al. Enzymatic activity of methionine adenosyltransferase variants identified in patients with persistent hypermethioninemia. Mol Genet Metab. 2010;101:172–7.

38. Sinclair G, Vianca H, Mahmootgoli S, Salvaronco R, Stockle TO, Mudd SH. Autosomal dominant hypermethioninemia identified by newborn screening due to multiple MAT1A mutations in an ethnically diverse population. 2013. Abstract. http://www.apphiorg/conferences/proceedings/Pages/2013/APH- NBS-Genetic-Testing-Symposium.aspx

39. Tada H, Takashai J, Borkovich AJ, Yamamoto S, Kohno Y. Reversible white matter lesion in methionine adenosyltransferase VIII deficiency. AJNR Am J Neuroradiol. 2004;25:1845–53.

40. Linnebank M, Lagler F, Muntau AC, Roschinger W, Olsemoller B, Fowler B, et al. Methionine adenosyltransferase (MAT) I/III deficiency with concurrent hyperhomocysteinemia: two novel cases. J Inherit Metab Dis. 2005;28:167–8.

41. Gaull G, Sturman JA, Raiha NC. Development of mammalian sulfur metabolism: gene products. Trends Genet. 1997;13:51–2.

42. C. Chien YH, Mudd SH, Lee NC, Huang AC, Hwu WL. Spectrum of hypermethioninemia in Taiwan Japanese. J Inherit Metab Dis. 2007;30:214–5.

43. Ito M, Kotani Y, Matsuda J, Chihri Y, Naito E, Morii K, et al. A methionine adenosyltransferase (MAT) deficiency patient treated with diet therapy. J Inherit Metab Dis. 2003;26:76.

44. Stabler SP, Meadow C, Wolfszdo, Jaekus JA, Kraus JP, Allen RH, et al. Elevated plasma total homocysteine in severe methionine adenosyltransferase I/III deficiency. Metabolism. 2002;51:881–8.

45. Mudd SH. Hypermethioninemias of genetic and non-genetic origin: A review. Am J Med Genet C Semin Med Genet. 2011;157C:3–2.

46. Stabler SP, Meadow C, Wolfszdo, Jaekus JA, Kraus JP, Allen RH, et al. Elevated plasma total homocysteine in severe methionine adenosyltransferase I/III deficiency. Metabolism. 2002;51:881–8.

47. Landau YE, Levy HL, James PM. Transient neonatal hypermethioninemia in maternal MAT I/III deficiency. Mol Genet Metab. 2012;102:298.

48. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 2007.

49. Stabler SP, Meadow C, Wolfszdo, Jaekus JA, Kraus JP, Allen RH, et al. Elevated plasma total homocysteine in severe methionine adenosyltransferase I/III deficiency. Metabolism. 2002;51:881–8.

50. Mudd SH. Hypermethioninemias of genetic and non-genetic origin: A review. Am J Med Genet C Semin Med Genet. 2011;157C:3–2.
56. Spector R, Coakley G, Blakely R. Methionine recycling in brain: a role for folates and vitamin B12. J Neurochem. 1980;34:132–7.
57. Dever JT, Elfara AA. The biochemical and toxicological significance of hypermethioninemia: new insights and clinical relevance. Expert Opin Drug Metab Toxicol. 2010;6:133–46.
58. Mudd SH, Levy HL, Tangeman E, Boujet C, Buist N, Davidson-Mundt A, et al. Isolated persistent hypermethioninemia. Ann J Hum Genet. 1995;57:882–92.
59. Smith QR, Momma S, Aoyagi M, Rapoport SL. Kinetics of neutral amino acid transport across the blood–brain barrier. J Neurochem. 1987;49:1651–8.
60. de Groot MJ, Hoekema M, Blau N, Reijngoud DJ, van Spronsen FJ. Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol Genet Metab. 2010;99 Suppl 1:586–9.
61. Weglage J, Pietsch M, Feldmann R, Koch HG, Zschocke J, Hoffmann G, et al. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res. 2001;49:532–6.
62. Hick L, Funk D, Geller A, Kotb M. Expression and functional interaction of S-adenosylmethionine is substrate for carrier-mediated transport at the blood–brain barrier in vitro. Brain Res. 2002;942:46–50.
63. Surtees R, Leonard J, Austin S. Association of demyelination with deficiency of S-adenosylmethionine. Eur J Pediatr. 1991;150:185–9.
64. Chishiy M, Reichel A, Abbott NJ, Begley DJ. S-adenosylmethionine is substrate for carrier-mediated transport at the blood–brain barrier in vitro. Brain Res. 2002;942:46–50.
65. Metz J. Pathogenesis of cobalamin neuropathy: deficiency of nervous system S-adenosylmethionine? Nutr Rev. 1993;51:12–5.
66. Halim AB, LeGros L, Geller A, Kotb M. Expression and functional interaction of the catalytic and regulatory subunits of human methionine adenosyltransferase in mammalian cells. J Biol Chem. 1999;274:29720–5.
67. Mitsui K, Teraoka H, Tsukada K. Complete purification and immunochemical analysis of S-adenosylmethionine synthetase from bovine brain. J Biol Chem. 1988;263:11211–6.
68. Martinez-Chantar ML, Latasa MU, Varela-Rey M, Lu SC, Garcia-Trevijano ER, Mato JM, et al. L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells: role of S-adenosylmethionine. J Biol Chem. 2003;278:19885–90.
69. Gomes Trolin C, Ekblom J, Oreland L. Regulation of methionine adenosyltransferase catalytic activity and messenger RNA in SH-SYSY human neuroblastoma cells. Biochem Pharmacol. 1998;55:567–71.
70. Gonzalez MP, Varela-Mareiras G, Selhub J, Paul L, Pajares MA. Methionine Adenosyltransferase Expression Depends on Methionine Concentrations in the Culture Media. Ann Nutr Metab. 2013;63:1342.
71. Young SN, Shalchi M. The effect of methionine and S-adenosylmethionine on S-adenosylmethionine levels in the rat brain. J Psychiatry Neurosci. 2005;30:444–8.
72. Smantantinoli G. Pharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamics. Am J Med. 1987;83:35–42.
73. Bottiglieri T, Godfrey P, Flynn T, Caneu MW, Toone BK, Reynolds EH. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1999;63:1069–76.
74. Mudd SH, Jenden DJ, Capdevila A, Roch M, Levy HL, Wagner C. Isolated hypermethioninemia: measurements of S-adenosylmethionine and choline. Metabolism. 2000;49:1543–7.
75. da Costa KA, Rai KS, Cracknecscu CN, Parikh K, Mehedint MG, Sanders LM, et al. Dietary docosahexaenoic acid supplementation modulates hippocampal development in the Pemt/→/ mouse. J Biol Chem. 2010;285:1008–15.
76. Innis SM. Dietary omega 3 fatty acids and the developing brain. Brain Res. 2008;1237:35–43.
77. Hazelwood S, Bernardini I, Shoteierou M, Tangerman A, Guo J, Mudd H, et al. Normal brain myelination in a patient homozygous for a mutation that encodes a severely truncated methionine adenosyltransferase I/II. Ann J Med Genet. 1998;75:395–400.
78. Yap S, Rushe H, Howard PM, Naughten ER. The intellectual abilities of early-treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2001;24:437–47.
79. Kim SZ, Santamaria E, Jeong TE, Levy HL, Mato JM, Corrales FJ, et al. Methionine adenosyltransferase I/II deficiency: two Korean compound heterozygous siblings with a novel mutation. J Inherit Metab Dis. 2002;25:661–71.
80. Yanamoto S, Takahashi J, Mako G, Murayama K, Kanazawa M, Kohno Y. Brain demyelination in a patient with persistent hypermethioninemia. J Inherit Metab Dis. 2003;26:89.